Alexander MeierPartner at Preu Bohlig & Partner
Dr. Alexander Meier has more than 18 years of relevant professional experience as an external attorney and inhouse lawyer in the field of pharmaceutical law (life science). He specializes in European and German regulatory law relating to chemical and biological pharmaceuticals (including advanced therapies) and medical devices, and all related regulatory issued. Most recently, Alexander Meier worked for Hoyng Rokh Monegier in Amsterdam and Munich. As of May 2006, Alexander Meier worked for Novartis for 11 years with increasing responsibilities, first in Holzkirchen for the Generics Division as Head of Legal and Compliance Office for Sandoz/Hexal Germany and thereafter in the Group Headquarters in Basel, where he served, amongst others as, Global Head, Legal of TechOps, Regulatory and Development for Novartis Pharma for the Originator Division and as Head of Legal, Global and Pharma Drug Development for Novartis across all Divisions. This included in particular legal advice for all global development functions as well as and regulatory issues for the entire product portfolio of Novartis’ business areas (general medicine and oncology including cell & gene therapy products) including compliance.
Dr. Alexander Meier advises and represents national and international pharmaceutical and medical device companies in all areas of pharmaceutical law (life science) (AMG including GxP and Medical Affairs, HWG, MPG), competition law and food law. He is extensively involved in regulatory affairs as well as in product liability and compliance. A particular specialization of the firm’s legal advice lies in the field of biopharmaceuticals, in particular cell and gene therapy products, as well as advanced therapy medicinal products (ATMPs). With over 18 years of experience in Germany and Europe, he has particularly extensive practical knowledge of regulatory exclusivity rights (document protection and orphan market exclusivity).
Dr. Alexander Meier is the author of numerous specialist publications and a regular speaker on all aspects of pharmaceutical law. He is co-editor and author of the second edition of the textbook “Pharmarecht” published by C.H.Beck.